Targeting the "undruggable" RAS with biologics

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS proteins are key drivers in human cancer development.
• Targeting RAS is a major focus for cancer therapy.
• Existing therapies primarily target KRAS^G12C, leaving other mutations unaddressed.

Purpose of the Study:

• To review the emerging field of anti-RAS biologics.
• To highlight novel therapeutic vulnerabilities in oncogenic RAS.
• To discuss the potential of biologics in developing new anti-RAS therapies.

Main Methods:

• Literature review of anti-RAS biologic research.
• Analysis of current and emerging anti-RAS therapeutic strategies.
• Discussion of preclinical and clinical developments in anti-RAS biologics.

Main Results:

• Several anti-RAS biologics have been developed.
• These biologics reveal new vulnerabilities in oncogenic RAS.
• Progress has been made in targeting specific RAS mutations.

Conclusions:

• Anti-RAS biologics represent a promising new avenue for cancer treatment.
• Further development is needed to target a broader range of RAS mutations.
• Biologics hold potential for novel anti-RAS therapies.